PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Opening snapshot: European stocks bounce

Tue, 27th Mar 2018 08:27

* European stocks rise >1 pct * Wall Street, Asia surged on China-U.S. trade talks March 27 - Welcome to the home for real-time coverage of European equity markets brought toyou by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger toshare your thoughts on market moves: helen.reid.thomsonreuters.com@reuters.net OPENING SNAPSHOT: EUROPEAN STOCKS BOUNCE (0727 GMT) European shares are joining in a global relief rally in risk assets as trade tensions ease.Sectors which were hit hardest over the past few sessions, such as autos, basicresources and tech, are the biggest gainers early on. The biggest individual mover so far is France's Casino, which has jumped around 6percent after its Monoprix chain agreed to sell products via Amazon. This shows just how crucialit is for companies to demonstrate that they are keeping up with the times and exploring onlineopportunities. Regarding the spreadbetters and ESMA's restrictions on CFDs, it's a mixed bag following adecidedly negative start, with IG down slightly but both CMC and Plus500 making gains. Here's your opening snapshot: (Kit Rees) ***** WHAT'S ON THE RADAR FOR THE OPEN (0649 GMT) European stocks are set to surge with futures climbing 1.4 to 2.2 percent across the majorbenchmarks, riding the wave of rising equities worldwide after Wall Street indices had theirstrongest day in years as investors bet on a trade war détente. Retail stocks will be ones to watch after French supermarket group Casino struck a deal withAmazon to make groceries from its Monoprix chain of stores available on Amazonā€™s Prime Nowservice to Parisian customers this year. The partnership extends Amazonā€™s reach into the European grocery market, and while Casinoshares are seen rising 3 to 5 percent, the news could shake investorsā€™ confidence in retailnames that are more behind the curve. In M&A news, GlaxoSmithKline shares are expected to rise 3 to 4 percent after the pharmacompany announced it was buying out Novartisā€™ stake in their consumer healthcare joint venturefor $13 billion. Novartis is seen up 1 percent. Another corporate break-up story from Akzo Nobel which is to sell its Specialty Chemicalsbusiness for $12.6 billion to U.S. private equity firm Carlyle Group and Singaporeā€™s GIC ā€“ending the simplification effort which began as the paint maker sought to evade a takeover fromPPG in April 2017. Its shares are set to rise 2 to 4 percent. Spreadbetters such as IG Group, CMC Markets and Plus500 are seen down 2 percent premarketafter a move from European markets regulator ESMA to crack down on contract-for-difference (CFD)trades offered to retail clients. (Helen Reid) ***** MORNING HEADLINE ROUND-UP (0637 GMT) Here's a round-up of key headlines for European companies this morning - note the news thatCasino's Monoprix is going to be teaming up with Amazon to sell groceries on Prime Nowin Paris. Casino's shares are seen up as much as 5 percent premarket. GSK buys Novartis stake in consumer healthcare venture for $13 bln H&M Q1 pretax dives in line with expectations, flags more markdowns Deutsche Bank seeks to replace CEO with Goldman executive -report Amazon wins grocery foothold in France through Monoprix deal Galliford Try to raise 158 mln stg to cover Carillion project costs Nordex sees lower sales, margins as wind industry tightens Akzo Nobel to sell unit to Carlyle, GIC for 10.1 bln euros (Kit Rees) ***** EUROPEAN STOCK FUTURES SURGE (0610 GMT) Futures for the major European stock markets have opened sharply higher, rising 1.1 to 1.8percent with the DAX in the lead, as investors place bets on a strong bounce at the open. Meanwhile analysts are still mulling what caused the late-afternoon slump in sharesyesterday. Here's Peel Hunt strategist Ian Williams: "The trigger was not immediately obvious with neither further strength in the euro, or thelatest wave of Russian diplomatic expulsions, especially convincing reasons for such a move. Amore worrying interpretation is that investors may be taking advantage of even the most modestof rallies to lighten their equity exposure." If Williams is right we may see a volatile session today as well - but for the moment allsigns are pointing to a strong rebound for the European market. (Helen Reid) ***** BULLS TO KEEP THE UPPER HAND (0548 GMT) Goldman Sachs' Bear/Bull indicator is above 70%, a level normally associated with animminent bear market (see below). But the GS team led by Peter Oppenheimer reckons relativelyattractive equity valuations will protect markets from a big drawdown, at least for now. There's also a wide spread in the underlying variables behind the indicator: very low levelsof unemployment and strong growth momentum are normally accompanied with "tighter monetarypolicy, a flatter yield curve and rising core inflation," notes GS. "But these remain subduedand without these risks rising, the prospect of a recession and 'cyclical' bear market is low." Valuation meanwhile is becoming less of a risk, they add - the forward consensus PE for theMSCI AC World is back to its 1990 average and below its average excluding Tech stocks. Highvaluations are mostly confined to the U.S. market. Furthermore, free cash flow yields have increased along with P/E ratios, and the total cashreturn from equities (dividend yield + buyback yield) has risen in most markets. So the overall message from GS is: don't panic! The bulls will prevail, at least for now... (Helen Reid) ***** MORNING CALL: EUROPEAN STOCKS TO BOUNCE BACK STRONGLY(0520 GMT) Good morning and welcome to Live Markets. Risk appetite is back! European stocks are called to open strongly higher today after a weakclose yesterday. They're being pushed up by the equities rally on Wall Street and in Asiaovernight greeting news that the U.S. and China are holding behind-the-scenes trade talks. White House officials are asking China to cut tariffs on imported cars, allow foreignmajority ownership of financial services firms and buy more U.S.-made semiconductors, accordingto a person familiar with the discussions. Asian shares bounced back overnight with the Nikkei up 1.7 percent and Chinese blue-chipsgaining 1.2 percent. The gains came after a stellar session on Wall Street with the Dowdelivering its third-biggest point gain ever, jumping 2.8 percent, while the S&P 500 gained 2.7percent and the Nasdaq surged up 3.3 percent. A negative currency effect could weigh on European stocks today, though, with the euro stillnear the six-week high against the dollar it touched yesterday. It had its biggest one-daypercentage gain since June 2017 yesterday. Spreadbetters call the DAX 183 points higher at 11,971, the CAC 40 up 60 points at 5,127,and the FTSE 100 78 points higher at 6,966. (Helen Reid) ***** (Reporting by Helen Reid, Danilo Masoni, Julien Ponthus and Kit Rees)
More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.